Efficacy of Recombinant Human Clara Cell 10 KDA Protein (CC10) Administered to Premature Neonates with Respiratory Distress Syndrome

727540
Pediatrics
Dr. Jeffrey Shenberger
Baystate Medical Center 759 Chestnut Street Springfield, MA 01199

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants characterized by marked inflammation and alveolar hypoplasia.  Presently there are no known medications which prevent the development of BPD.   The purpose of the present study is to evaluate the ability of a single intratracheal dose of recombinant human CC10 to prevent the development of long-term respiratory complications and BPD in ventilated premature infants.  

Inborn preterm neonates of either sex with a gestational age of 24 weeks up to 29 weeks, clinical course consistent with RDS, endotracheal surfactant administration within 24 hours from birth
Dr. Jeffrey Shenberger
413-794-5370